Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): Survival and clinical activity by subgroup analysis Meeting Abstract

  

Authors:	Brahmer, J. R.; Horn, L.; Gandhi, L.; Spigel, D. R.; Antonia, S. J.; Rizvi, N. A.; Powderly, J. D.; Heist, R. S.; Carvajal, R. D.; Jackman, D. M.; Sequist, L. V.; Smith, D. C.; Leming, P. D.; Topalian, S. L.; Hodi, F. S.; Sznol, M.; Harbison, C.; Kollia, G.; Gupta, A. K.; Gettinger, S. N.
Abstract Title:	Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): Survival and clinical activity by subgroup analysis
Meeting Title:	50th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	32
Issue:	15 Suppl.
Meeting Dates:	2014 May 30-Jun 3
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2014-05-20
Language:	English
ACCESSION:	WOS:000358613204174
PROVIDER:	wos
DOI:	10.1200/jco.2014.32.15_suppl.8112
Notes:	Meeting Abstract: 8112 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/80855